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Objectives: Noninvasive objective tests are needed to diagnose primary Sjogren’s syndrome 
(pSS) and to evaluate treatment responses. Ultrasound imaging of the salivary glands is rapid 
and noninvasive. Recent open-label studies suggested that anti-CD20 (rituximab) may be 
effective in pSS. The purpose of this study was to look for ultrasound evidence of the effects 
of rituximab in pSS.
Methods: We compared 16 patients fulﬁ  lling the new American-European consensus group 
criteria for pSS to 9 controls, using B-mode ultrasound features (parenchymal homogeneity 
and gland size) and Doppler waveform analysis of the transverse facial artery of parotid glands. 
We compared the same parameters in the patients before and after 12 weeks of intravenous 
rituximab therapy.
Results: Compared to controls, untreated patients had signiﬁ  cant abnormalities in salivary 
gland structure (p  0.0001) and parotid size (2.05 ± 0.33 cm versus 1.70 ± 0.28 cm; p = 0.001). 
Doppler waveform analysis showed signiﬁ  cant differences before, but not after, lemon stimu-
lation between untreated patients and controls. After rituximab treatment, signiﬁ  cant size 
reductions were noted in the parotids (2.05 ± 0.3 cm at baseline and 1.86 ± 0.27 cm at week 
12; p = 0.002) and submandibular glands (2.02 ± 0.54 cm at baseline and 1.66 ± 0.34 cm at week 
12; p = 0.001). Doppler resistive indices after lemon stimulation were signiﬁ  cantly increased 
after rituximab treatment.
Conclusion: Salivary gland measurements and blood inﬂ  ow responses to salivary stimulation 
as assessed by ultrasound hold promise as objective noninvasive tools for evaluating rituximab 
effects in patients with pSS.
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Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disorder characterized 
by lymphocytic inﬁ  ltrates in the lachrymal and salivary glands. Dryness of the eyes 
(keratoconjunctivitis sicca) and mouth (xerostomia) are the main clinical features. 
Histology shows lymphocytic inﬁ  ltration and destruction of the affected glands.
Sjögren’s syndrome is considered primary in patients who have no underlying con-
nective tissue disease. Investigations must be performed to document the ocular and oral 
dryness; to rule out connective tissue disease; and to conﬁ  rm that the dryness is not due to 
other conditions such as diabetes mellitus, hypovolemia, sarcoidosis, infection, respira-
tory or renal insufﬁ  ciency, smoking, or medications. These investigations include salivary 
ﬂ  ow measurement, sialochemistry, sequential salivary scintigraphy, and sialography 
using liposoluble or hydrosoluble contrast material. Histological examination of minor 
salivary gland biopsies may be the most speciﬁ  c investigation for diagnosing pSS.Biologics: Targets & Therapy 2007:1(3) 312
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In recent years, ultrasonography has been described as a 
simple noninvasive tool for identifying salivary gland changes 
in patients with pSS (Bradus et al 1988; Kawamura et al 1990; 
De Vita et al 1992; Ariji et al 1996; Yoshiura et al 1997; Mandel 
and Orchowski 1998; Makula 2000; Salafﬁ   et al 2000; Yousem 
et al 2000; Howlett 2003; Gritzmann 2003), although the data 
are somewhat conﬂ  icting. Doppler waveform analysis was 
found useful for detecting blood ﬂ  ow abnormalities in the sub-
mandibular glands of patients with pSS compared to controls 
(Chikui et al 2000). Resistive and pulsatility indices of the 
facial artery were decreased in the patients, and responses to 
lemon stimulation were less marked than in the controls (Chikui 
et al 2000). Another study (Carotti et al 2001) evaluated blood 
inﬂ  ow through the facial artery to the submandibular glands and 
through the external carotid artery to the parotids but failed to 
evaluate the transverse facial artery, which contributes to sup-
ply the parotid glands. Given the importance of parotid gland 
involvement in pSS, we believe that the transverse facial artery 
should be evaluated routinely.
Until recently, the only treatments available for pSS were 
symptomatic agents designed to relieve the symptoms of dry-
ness. These agents had no effect on the course of the disease. 
A case-report describing improvement of Sjögren’s syndrome 
after rituximab therapy for marginal zone lymphoma was 
published in 2003 (Somer et al 2003). Since then, three open-
label studies have suggested that rituximab may be effective 
in pSS (Pijpe et al 2005; Seror et al 2007; Devauchelle-Pensec 
2007). To further investigate the effects of rituximab and other 
biologics in pSS, tools capable of evaluating salivary gland 
size, structure, and function are needed.
The objective of this study was to evaluate the ability of 
ultrasonography and Doppler waveform analysis to detect 
changes induced by rituximab therapy in patients with 
pSS. To this end, we measured parenchymal homogeneity, 
echogenicity, and size; as well as blood inﬂ  ow through the 
transverse facial artery before and after lemon stimulation. 
These parameters were recorded once in controls and twice, 
before and after rituximab therapy, in patients with pSS.
Materials and methods
Study participants
Patients
We recruited patients seen for pSS between April and Decem-
ber 2004 at the rheumatology and internal medicine depart-
ments of the Brest Teaching Hospital. Patients were eligible 
if they met the new American–European Consensus Group 
criteria for pSS (Vitali et al 2002) and had active disease 
deﬁ  ned as scores greater than 50 mm on two of four 100-mm 
visual analog scales (VAS) that evaluated global disease 
activity, pain, sicca syndrome, and fatigue, respectively. 
Patients were excluded if they had secondary Sjögren’s 
syndrome or presence of any marker for autoimmune disease 
other than pSS. All histological specimens were examined by 
the same pathologist (IQR), who determined the Chisholm 
score (grades 1 to 4) (Chisholm and Mason 1968).
Controls
Because salivary gland abnormalities may differ across 
patients with pSS according to disease duration and to the 
balance between lymphocyte inﬁ  ltration and tissue destruc-
tion, we enrolled 9 healthy volunteers as a control group. The 
controls had a normal medical history, with no symptoms of 
xerostomia or keratoconjunctivitis sicca; their physical ﬁ  nd-
ings were normal and they were not using medications.
Rituximab treatment (patients only)
All patients received 375 mg/m2 of rituximab by intravenous 
infusion twice at a 1-week interval. The infusion rate was 
increased from 50 mg/hour initially, in steps of 50 mg/hour 
every 30 minutes, to a maximum of 400 mg/hour if well 
tolerated. Hypersensitivity or infusion-related reactions were 
recorded every 30 minutes. No corticosteroids or immuno-
suppressants were used concomitantly.
Ultrasound protocol (patients and controls)
Ultrasonography was performed once in the controls and 
twice in the patients, before and after the 12-week course of 
rituximab therapy. Ultrasound images were acquired in the 
supine position with the neck hyperextended and the head 
slightly turned to the side opposite the glands being exam-
ined. Pulsed Doppler and B-mode ultrasonography studies 
were performed using an ATL HDI machine (ATL, Boswell) 
equipped with a linear 12-MHz probe and a 5- to 7-MHz 
convex probe. The 12-MHz probe was used to determine 
echostructure and the 5- to 7-MHz probe to measure gland 
size. Both bilateral parotid and submandibular glands of each 
patient were scanned in 2 planes, parallel and perpendicular 
to the submandibular plane. The sonographic images of both 
parotid and submandibular glands scanned parallel to the sub-
mandibular plane were used for the analysis. Axial and coronal 
views of the parotid and submandibular glands were obtained. 
The transverse facial artery, which supplies the parotid gland, 
was examined. All ultrasound parameters were evaluated by 
the same ultrasonographist (SJJ) (who do not have the patient 
characteristics) to eliminate interobserver variability.
The normal parotid is homogeneous by ultrasonogra-
phy. Echogenicity is similar to that of the thyroid gland Biologics: Targets & Therapy 2007:1(3) 313
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and greater than that of the masseter. We used a previously 
reported ultrasound grading procedure (De Vita et al 1992) 
based on parenchymal homogeneity, echogenicity, gland 
size, and posterior glandular border: Grade 0, normal glands; 
Grade 1, regular contour, small hypoechogenic areas without 
echogenic bands, normal or increased gland size (mean 20 ± 
3 mm for the parotids and 13 ± 2 mm for the submandibular 
glands), and deﬁ  nite echogenic border; Grade 2, regular con-
tour, multiple hypoechogenic areas usually 2 mm without 
echogenic bands; Grade 3, regular or ill-deﬁ  ned contour, 
multiple hypoechogenic areas and hyperechogenic bands, 
and no visible posterior glandular border; Grade 4, irregular 
contour, multiple hypoechogenic areas 6 mm or multiple 
calciﬁ  cations with echogenic bands, decreased gland size, 
and no visible posterior glandular border. The ultrasound 
ﬁ  ndings were considered abnormal if either parotid or sub-
mandibular glands were Grade 1 or higher.
Color Doppler was used to visualize the transverse facial 
artery (main branch to the parotids) near the auditory canal. 
Pulse repetition frequency was 700 Hz, and color gain was 
adjusted dynamically to maximize visualization of the 
arteries while minimizing noise. Doppler waveforms were 
recorded, and resistive index and acceleration time were 
determined. Resistive index was computed as the differ-
ence between peak systolic and end-diastolic velocities over 
the peak systolic velocity. Acceleration time was the time 
interval from systolic ﬂ  ow onset to the ﬁ  rst peak and was 
recorded in milliseconds. These waveform parameters were 
determined before and after salivary stimulation with lemon 
juice. We placed 3 ml of lemon juice extract on the ﬂ  oor of 
the mouth and asked the patient to wait 10 seconds before 
swallowing. During these 10 seconds, before swallowing, we 
recorded the waveform on the left transverse facial artery.
Ethical aspects
The study design was approved by the institutional review 
board of the Brest Teaching Hospitals. All patients gave their 
written informed consent.
Statistical analysis
Version 12.0 of the Statistical Package for the Social Sci-
ences software for Windows (SPSS, Chicago, IL) was used. 
Data are reported as mean ± SD. Data from controls and 
untreated patients were compared using Mann-Whitney 
and chi-square tests. T o compare data in patients before 
and after rituximab, we used the Wilcoxon matched-pairs 
signed-rank test for paired data. P values less than 0.05 were 
considered signiﬁ  cant.
Results
Baseline characteristics of the controls 
and patients
Nine healthy volunteers (8 females and one male; mean age: 
60.2 ± 11.6 years) and 16 patients with pSS (14 females and 
two males; mean age: 54.9 ± 12.8 years) were included. Tests 
were positive for antinuclear antibody in all 16 patients, for 
anti-SSA in 13 patients, and for anti-SSB in 7 patients. Their 
characteristics have been previously published (Devauchelle-
Pensec et al 2007). All patients had an ultrasound evaluation 
at inclusion; 14 of the 16 treated patients had an ultrasound 
evaluation at all visits.
Comparison between patients
and controls
Parotid size and ultrasound grade were signiﬁ  cantly differ-
ent between the patients and controls (Table 1 and Figures 
1 and 2).
Table 1 Baseline characteristics of salivary glands of 16 patients with primary Sjögren’s syndrome (before treatment) and 9 healthy 
controls
Salivary glands  N = 18  N = 32  p value
  (9 healthy controls)  (16 patients)
Size of parotid glands (cm)  1.7 ± 0.28   2.05 ± 0.33 0.001
Size of submandibular glands  1.81 ± 0.30 2.02  ± 0.54 0.9
Sonographic grade (B mode)
0 18  (100%)  8  (25%)
≥1 0  24  (75%)  0.0001
Grade among group ≥1
1 0  7  (22%)
2 0  10  (31%)
3 0  6  (19%)
4 0  1  (3%)Biologics: Targets & Therapy 2007:1(3) 314
Jousse-Joulin et al
(a)( b)
 
(c)
Figure 1 High-resolution, 10 MHz, axial sonograms of parotid gland. Parenchymal pattern of the parotid gland in control (a) and patients (b, c).
(a)( b)
Figure 2 B-mode image of submandibular gland. (a) Homogenous parenchyma. (b) heterogenous parenchyma.Biologics: Targets & Therapy 2007:1(3)
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Blood ﬂ  ow in the controls was characterized by a high 
systolic peak and a prominent second peak of compliance, 
followed by low diastolic ﬂ  ow (Figure 3a). In the patients, 
ﬂ  ow was more uniform than in the controls, with blunted 
systolic and compliance peaks followed by a higher dia-
stolic ﬂ  ow (Figure 4a). Lemon stimulation was followed by 
increases in the compliance peak and diastolic ﬂ  ow in the 
controls (Figure 3b), whereas in the patients diastolic ﬂ  ow 
was similarly high before and after stimulation (Figure 3c, d). 
Thus, lemon stimulation induced no signiﬁ  cant changes in the 
waveform proﬁ  le of the transverse facial artery in the patients 
(Figure 4b). Basal resistive index values were signiﬁ  cantly 
lower in the patients than in the controls (0.75 ± 0.05 vs 0.81 
± 0.42; p  0.005). After lemon stimulation, however, resis-
tive index values were not signiﬁ  cantly different between 
the patients (0.72 ± 0.07) and the controls (0.73 ± 0.42). 
No signiﬁ  cant differences in acceleration time were noted 
between the patients and controls in the basal state (90 ms vs 
65 ms) or after lemon stimulation (82 ms vs 74 ms).
Comparison before and after 12 weeks 
of rituximab treatment in the patients
All 16 patients had parotid evaluation (32 parotid glands) 
and 13 of them had also submandibular evaluation (26 sub-
madibular glands). No changes in parenchymal homogeneity 
or echogenicity were noted after rituximab compared with 
baseline. However, gland size decreased signiﬁ  cantly. Parotid 
gland size diminished from 2.05 ± 0.3 cm to 1.86 ± 0.27 cm 
(p = 0.002) (Figure 5) and submandibular gland size from 
2.02 ± 0.54 cm to 1.66 ± 0.34 cm (p = 0.001).
We sought to determine whether the structural changes 
assessed based on the US grade in the salivary glands 
correlated with the resistive index. In the 5 patients with 
Grade 1 or 2 glands, the resistive index was unchanged 
after lemon stimulation (0.77 ± 0.04 under basal conditions 
vs. 0.80 ± 0.05 after stimulation). In the 9 patients with 
grade 3 or 4 glands, the resistive index fell signiﬁ  cantly 
from 0.74 ± 0.05 under basal conditions to 0.71 ± 0.07 after 
stimulation (p = 0.003).
Under basal conditions, the resistive indices were similar 
at baseline (0.75 ± 0.05) and after rituximab (0.77 ± 0.1) 
(p = NS). After lemon stimulation, at W0, no increase in 
resistive index occurred. In contrast, at W12 after treatment, 
a signiﬁ  cant increase was seen (RI 0.77 ± 0.01 at W0 to 
0.79 ± 0.08 at W12) (p  0.05) with a systolic peak, a 
compliance peak, and a diastolic ﬂ  ow. Further, stimulation 
with lemon at week 12 changed the waveform proﬁ  le of the 
transverse facial artery and had a normal appearance.
Correlation between rituximab 
treatment efﬁ  cacy and sonographic 
modiﬁ  cations
Clinical and biological results have been previously pub-
lished (Devauchelle-Pensec et al 2007). At week 12, subjec-
tive variables including fatigue and dryness were signiﬁ  cantly 
improved (p  0.05). Seven patients of 16 at week 24, 7 of 
15 at week 32, and 9 of 15 at week 36 improved their 4 VAS 
scores: global, pain, fatigue, and dryness. In contrast, there 
were no signiﬁ  cant changes in the unstimulated salivary 
ﬂ  ow rate; the salivary gland focus score; the ophthalmologic 
evaluation; the titers of ANA, anti-SSA, and anti-SSB; 
complement levels; CICs and levels of serum IgG and IgA. 
There was a dramatic reduction in B cells of the blood and 
the salivary gland (SG) in all cases. We failed to demonstrate 
any correlation between clinical (VAS), biological (gam-
maglobulinemia, CD19 depletion) or histological (Chisholm 
grade) data and glandular size evaluated by ultrasound.
Discussion
The diagnosis of pSS rests on history-taking, physical exami-
nation, laboratory tests, salivary gland biopsy, and sialography 
or salivary gland scintigraphy. However, patients may report 
symptoms of dryness yet have normal ﬁ  ndings from tests for 
autoimmunity and lip biopsies. Sialography has been widely 
used to diagnose Sjögren’s syndrome but causes discomfort 
or pain during the examination. In a recent comparison of 
magnetic resonance imaging (MRI) and ultrasonography, 
both techniques showed structural changes in the parotid 
glands (Makula 2000; Miedany et al 2004). However MRI is 
more costly and less widely available than ultrasonography. 
Ultrasonography is a simple, noninvasive, and inexpensive 
tool that produces real-time images and does not expose the 
patient to radiation. Thus, ultrasonography is emerging as a 
good method for objectively evaluating the salivary glands.
Several typical ultrasound features of pSS have been 
described (Kawamura et al 1990; Mandel and Orchowski 
1998; Makula 2000), although their incidence is low. 
Absence of typical ultrasound ﬁ  ndings at the ﬁ  rst visit should 
lead to sialography (Yousem et al 2000). In contrast, when 
the ultrasound scan suggests pSS, laboratory tests and/or lip 
biopsy can be performed. Signiﬁ  cant differences in B-mode 
ultrasound features have been reported between patients 
with pSS and controls (Makula et al 1996). For instance, 
the salivary gland parenchyma is heterogeneous in pSS and 
homogeneous in healthy individuals. In our study, the images 
were normal in the controls (grade 0), whereas abnormalities Biologics: Targets & Therapy 2007:1(3) 316
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(a) (b) 
(c) (d)
Figure 3 At baseline. (a) Doppler waveform without lemon stimulation: control population. High systolic peak and a prominent following compliance peak, followed by 
a low diastolic ﬂ  ow (RI = 0.88). (b) Doppler waveform with lemon stimulation: control population. Physiologic changes in vasculature when parotid gland is stimulated in 
controls. Level of systolic and diastolic ﬂ  ow is increased (RI = 0.91). (c) Doppler waveform in patient population without stimulation. We noted a decreased impedance in 
parotid vessels with a decrease RI (RI = 0.77). (d) Doppler waveform with lemon stimulation: patients. The waveform proﬁ  le is the same before and after stimulation.
    (a) (b)
Figure 4 Patient population treated by anti-CD20. (a) Pss patient population without stimulation: the resistive indice is clearly decreased (b) Pss patient population with 
lemon stimulation: the resistive indice is increased.Biologics: Targets & Therapy 2007:1(3) 317
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in structure and size were noted in the patients. In our popula-
tion, the size of parotid glands was signiﬁ  cantly higher in the 
patients than in the controls. At the acute stage of pSS, the 
salivary glands are swollen and hypoechogenic (Ariji et al 
1996; Salafﬁ   et al 2000), often with marked heterogeneity 
due to inﬂ  ammation, node enlargement, and myoepithelial 
hyperplasia. Furthermore, multiple cysts are found (Bradus 
et al 1988). In long-standing disease, in contrast, the sali-
vary glands are usually small, hypoechogenic, and poorly 
demarcated (Gritzmann 2003; Howlett 2003). We found no 
signiﬁ  cant difference in submandibular gland size between 
the controls and patients, probably because these glands are 
more difﬁ  cult to delineate than the parotids. Another hypoth-
esis could be that the absence of salivary gland hypertrophy 
at baseline explains the lower response to treatment.
Color Doppler sonography revealed salivary gland 
hyperemia in the patients with pSS (Martinoli et al 1994). 
Recently, color Doppler sonography was used to evaluate the 
vascular anatomy of the salivary glands in normal individu-
als (Martinoli et al 1994; Ariji et al 1998; Chikui et al 2000) 
and in patients with pSS (Martinoli et al 1994; Chikui et al 
2000). Chikui and colleagues (2000) reported abnormalities 
in Doppler waveforms from the facial artery in patients with 
Sjögren’s syndrome compared with controls. Color Doppler 
evidence of salivary gland hyperemia has been described in 
patients with pSS (Gritzmann 2003). Hyperemia may cause 
a decrease in the resistive index of the facial artery. Martinoli 
and colleagues (1994) used color Doppler to evaluate the 
vascular anatomy of the salivary glands and the physiologic 
changes induced by lemon-juice stimulation. Stimulation led 
to a marked increase in color signals within the parenchyma 
and to the development of an aliasing artifact due to increasing 
ﬂ  ow velocities; arterial impedance decreased in the salivary 
vessels, causing the resistive index to diminish (Martinoli 
et al 1994). Resistive index values returned to normal within 
20 seconds after the lemon juice was swallowed (Martinoli 
et al 1994). Carotti and colleagues (2001) reported that peak 
systolic velocity was more sensitive than the resistive index: 
0
0,5
1
1,5
2
2,5
3
W0 W12
Figure 5 Individual evolution of the parotid size of the patients before (W0) and after (W12) rituximab treatment.Biologics: Targets & Therapy 2007:1(3) 318
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in their study, resistive index values from the parotids and 
submandibular glands showed no signiﬁ  cant changes after 
lemon stimulation in patients with pSS or in controls.
We showed that in healthy individuals the transverse 
facial artery generated a biphasic Doppler waveform, with 
a high systolic peak followed by a prominent compliance 
peak then by low diastolic ﬂ  ow. Normally, lemon stimulation 
increases the compliance peak and diastolic ﬂ  ow (Martinoli 
et al 1994). The Doppler waveform changes in the normal 
parotid glands after lemon stimulation were consistent with 
increased blood ﬂ  ow in the gland during secretory activity. 
In the patients with pSS, the resistive indices were signiﬁ  -
cantly lower before stimulation than in the controls, and after 
stimulation the response of the transverse facial artery was 
blunted. As a result, the resistive index values after stimula-
tion were similar in the healthy controls and the patients with 
pSS. A possible explanation for the impaired responses to 
stimulation in pSS is that the gland, being already hyperemic 
under basal conditions, may be refractory to stimulation. 
Moreover, in the pSS patients, the severity of gland damage 
assessed by ultrasound correlated with the resistive index. 
Under basal conditions, resistive index values were not 
signiﬁ  cantly different between the subgroup with Grade 1 
and 2 disease and the subgroup with Grade 3 or 4 disease. 
After lemon stimulation, in contrast, a clear difference was 
noted between these two subgroups, with signiﬁ  cantly lower 
resistive index values in the patients who had more severe 
disease. Again, this ﬁ  nding suggests that basal hyperemia 
of the salivary glands may impair responses to stimulation. 
Whereas previous studies focused on the facial artery supply-
ing the submandibular glands, we showed that inﬂ  ow through 
the transverse facial artery supplying the parotid glands was 
also abnormal in patients with pSS.
In the patients with pSS, we evaluated the effects of ritux-
imab therapy on the ultrasound features of the salivary glands. 
rituximab is a chimerical monoclonal antibody against CD20, 
which is carried by B cells. Doppler waveform analysis was 
performed before and after 12 weeks of rituximab treatment, 
using the same protocol. Under basal conditions, Doppler 
waveform parameters were not signiﬁ  cantly different at 
baseline and after treatment (Figure 4). After lemon stimula-
tion, however, the difference was signiﬁ  cant, with rituximab 
inducing a higher systolic peak and lower diastolic ﬂ  ow. 
Furthermore, the waveform analysis of the transverse facial 
artery after stimulation, was abnormal before, but normal 
after, rituximab therapy. In particular, the resistive index 
value after stimulation in the treated patients was not very 
different from that in the controls. This favorable response 
to rituximab therapy may reﬂ  ect B-cell inﬁ  ltrate depletion 
and decreased inﬂ  ammation in the glands. We did not mea-
sure the acceleration time after rituximab therapy, because 
it was not signiﬁ  cantly different between the controls and 
the untreated patients.
In conclusion, both B-mode ultrasonography and color 
Doppler hold promise as noninvasive tools for studying 
salivary gland size and blood supply, either before or after 
stimulation of salivary secretion. Furthermore, color Doppler 
can be used to evaluate responses to treatment. However, 
additional studies of color Doppler as a monitoring tool are 
needed. We are currently starting a double blind prospective 
study evaluating rituximab versus placebo. If we conﬁ  rm its 
efﬁ  cacy, we will evaluate which parameters among clinical, 
biological or histological signs (Chisholm grade), new crite-
ria of activity (Vitali et al 2007), or sonographic grades, are 
the best predictor of rituximab response.
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